MedTrace Logo

Assessment of Quality of Life in Thalassemic Patients at Assiut University Hospital: A Single-center Experience

NCT05790980 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2023-03-30

No results posted yet for this study

Summary

The thalassemias are a group of inherited hematologic disorders caused by defects in the synthesis of one or more of the hemoglobin chains \[1\]. Thalassemia are classified into the alpha (α) and (β) thalassemia, which contain deficits in (α) and (β) globin production respectively (α)thalassemia are caused by decreased production of alpha-globin chains from chromosome 16. There are 4 types of (α) thalassemia: thalassemia silent carrier thalassemia carrier . Hemoglobin H disease thalassemia major Beta-thalassemia are caused by point mutations or more rarely deletions in the β-globin gene on chromosome 11, leading to reduced (β+) or absent (β0) synthesis of the β chains of hemoglobin. Imbalances of globin chains cause hemolysis and impair erythropoiesis \[4-7\]. β-thalassemia can be classified into: Beta Thalassemia major, Beta Thalassemia intermedia, Beta Thalassemia minor Thalassemia is a chronic disease that presents a range of serious clinical and psychological challenges.

The effects of thalassemia on physical health can lead to physical deformity, growth retardation, and delayed puberty \[9, 10\]. Its impact on physical appearance, e.g., bone deformities and short stature, also contributes to a poor self-image \[10, 11\]. Severe complications such as heart failure, cardiac arrhythmia, liver disease, endocrine complications, and infections are common among thalassemia patients \[8, 12\].

Conditions

Interventions

DEVICE

Abdominal ultrasound

Abdominal US to exclude splenomegaly and hepatomegaly or liver cirrhosis Echocardiology to show cardiac dysfunction

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-03-01
Completion
2025-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05790980 on ClinicalTrials.gov